Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Arizona Cancer Center
-
-
California
-
Fountain Valley, California, United States, 92708
- Pacific Coast Hematology Oncology Group
-
-
Florida
-
New Port Richey, Florida, United States, 34652
- Pasco Hernando Oncology
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60637
- The University of Chicago
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Greenebaun Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Nebraska Medical Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Nevada Cancer Research Foundation
-
Reno, Nevada, United States, 89502
- VA Sierra Nevada Health Care System
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- New Mexico Oncology Hematology Consultants
-
-
New York
-
New York, New York, United States, 10032
- Columbia Presbyterian Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburg Cancer Institute
-
-
Tennessee
-
Collierville, Tennessee, United States, 38017
- The Family Cancer Center
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, United States, 78705
- Southwest Regional Cancer Center
-
Dallas, Texas, United States, 75230
- Center for Oncology Research and Treatment
-
Tyler, Texas, United States, 75701
- East Texas Medical Center
-
-
Virginia
-
Danville, Virginia, United States, 24541
- Danville Hematology Oncology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens
- Must have measurable disease according to RECIST
- Eastern Cooperative Oncology Group performance status 0-1
- Adequate bone marrow, hepatic and renal function
- Ability to swallow capsules
- At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, at least 7 days from prior radiation therapy and have recovered from prior toxicities
- At least 3 weeks from major surgery
Exclusion Criteria:
- Non-small cell cancer histology contains a component of small cell lung cancer
- Previously untreated CNS metastasis or progressive CNS metastasis
- Prior treatment with a CDK inhibitor
- Currently receiving radiotherapy, biological therapy, or any other investigational therapy
- Uncontrolled intercurrent illness
- Having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer or basal cell skin cancer
- Pregnant or lactating women
- Known to be HIV-positive
- Active hepatitis B and/or hepatitis C infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Arm 1 with seliciclib
Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in.
Patients (randomized) continue on treatment if derived clinical benefit during run-in period.
|
1200 mg bid x 3 days every 2 weeks
Other Names:
|
|
PLACEBO_COMPARATOR: Arm 2 with placebo control
Randomized to placebo after run-in period.
|
1200 mg bid x 3 days every 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival
Time Frame: over the course of the study
|
Time until the disease starts progressing
|
over the course of the study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Chandra Belani, M.D., Milton S. Hershey Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Roscovitine
Other Study ID Numbers
Other Study ID Numbers
- CYC202-06-14 (A1)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.